CCC Project- Acute Coronary Syndrome

Completed

• Conditions: Acute Coronary Syndrome

• Registration Number: NCT02306616
• Lead Sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases

Brief Summary

To develop and implement quality improvement programs for the treatment of acute coronary syndrome (ACS) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of acute coronary syndrome.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-11
• Study First Submitted: 2014-11-29
• Study First Submitted QC: 2014-11-29
• Study First Posted: 2014-12-03
• Primary Completion: 2020-12
• Study Completion: 2020-12
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-26
• Last Update Posted: 2021-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 124363

Inclusion Criteria

Hospitalized patients with discharge diagnosis as acute coronary syndrome (including STEMI, NSTEMI and UAP) in 150 tertiary and 100 secondary hospitals.

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The overall composite of 11 performance measures for ACS care	Duration of hospital stay, an expected average of 1 week	Performance measures for ACS care including: 1. Proportion of patients received aspirin at arrival; 2. Proportion of patients received fibrinolytic therapy within 30 mins (STEMI); 3. Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI); 4. Proportion of patients received reperfusion therapy (STEMI); 5. Proportion of patients with aspirin prescribed at discharge; 6. Proportion of patients with clopidogrel or other P2Y12 inhibitors prescribed at discharge; 7. Proportion of patients with beta-blocker prescribed at discharge; 8. Proportion of patients with statin prescribed at discharge; 9. Proportion of patients received evaluation of left ventricular systolic function; 10. Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge; 11. Proportion of patients received smoking cessation advice/ counseling

Trial Locations

Locations (1)

Beijing An Zhen Hospital; 🇨🇳 Beijing, China